OpGen and Femasys: Pre-Market Action Unveiled
- September 29th, 2023
- 639 views
Shares of OpGen, Inc. (Nasdaq: OPGN) surged by more than 100% in pre-market trading following a regulatory filing with the Securities and Exchange Commission (SEC), requesting the SEC's consent to withdraw the company's Registration Statement on Form S-1, along with all related amendments and exhibits. It's important to note that the Registration Statement had not been declared effective, and no securities covered by it had been issued or sold.
$OPGN was trading at $0.48 pre-market, marking a substantial gain of $0.28 (+139.65%).
In other news, Femasys Inc. (Nasdaq: FEMY), a notable healthcare company, received a positive review from HC Wainwright & Co., which upheld its "Buy" rating on the stock and increased the price target from $5 to $13.
Considering Thursday's closing price of $1.52 for $FEMY, the revised price target suggests a substantial potential upside of $11.48 per share or approximately 753.68%, based on the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Global Scam Networks and the Corporate Infrastructure That Enables Them
November 06th, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
November 05th, 2026New Details Emerge in Amazon Ads Auction-Rigging Case
November 05th, 2026November 02nd, 2026
Member Login